Sanara MedTech’s CellerateRX surgical powder when used as an adjunct in high-risk spine surgery patients reduced complications and costs, according to a study.
Researchers used economic modeling to evaluate the clinical outcomes and direct medical costs of a cohort of complex spine patients, Sanara MedTech said in a March 11 news release. Patients were grouped either as being treated with CellerateRX as an adjunct or standard of care alone for managing acute surgical wounds after spine surgery.
Patients who had the CellerateRX treatment generated $3,852 in cost savings per case and a 0.007 quality of life years gain per case. The primary contributors to cost savings included reduced hospital readmissions and surgical revision procedures.
The study, published in the Journal of Medical Economics, concluded that CellerateRX can promote improved health outcomes and cost savings compared to standard care.
